No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AMED Amedisys
- 91.240
- 0.0000.00%
Trading Apr 23 09:30 ET
2.98BMarket Cap-304133P/E (TTM)
91.490High91.240Low785Volume91.490Open91.240Pre Close71.75KTurnover0.00%Turnover RatioLossP/E (Static)32.67MShares96.43652wk High2.79P/B2.91BFloat Cap73.10052wk Low--Dividend TTM31.94MShs Float325.120Historical High--Div YieldTTM0.27%Amplitude0.563Historical Low91.406Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
No Data
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Amedisys Is Maintained at Market Perform by Raymond James
Amedisys Is Maintained at Market Perform by Raymond James
Express News | Raymond James Maintains Market Perform on Amedisysto Market Perform
Amedisys Acquisition by UnitedHealth Unit Seen to Close Despite Potential DOJ Probe, RBC Says
Amedisys' (AMED) acquisition by UnitedHealth Group's (UNH) Optum unit is expected to be completed despite unconfirmed reports of a possible antitrust investigation by the US Department of Justice, RBC Capital Markets said in a note Monday.
Why Amedisys (AMED) Is a Top Value Stock for the Long-Term
Amedisys Is Maintained at Outperform by RBC Capital
Amedisys Is Maintained at Outperform by RBC Capital
Amedisys Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/25/2024 8.52% RBC Capital $97 → $100 Maintains Outperform 09/14/2023 9.6% Cantor Fitzgerald $100 → $101
Comments
$Amedisys(AMED.US$ divergency with good fundamental Also gap so it looks good and risk to rewards is acceptable
1
$Inhibikase Therapeutics(IKT.US$
learn from
$Amedisys(AMED.US$
$AMC Entertainment(AMC.US$
$Fulcrum Therapeutics(FULC.US$
JonesTrading analyst Soumit Roy initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $12.
$PharmaCyte Biotech(PMCB.US$
learn from
$Amedisys(AMED.US$
$AMC Entertainment(AMC.US$
$Fulcrum Therapeutics(FULC.US$
JonesTrading analyst Soumit Roy initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $12.
$PharmaCyte Biotech(PMCB.US$
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Kofi : Do u see it going above 100 ?